Meeting
2023 ASCO Genitourinary Cancers Symposium
Real-world treatment patterns and progression-free survival among patients with metastatic castration-resistant prostate cancer: Examining the benefits of sequential androgen receptor pathway inhibitor use.
Authors
Jeetvan Patel
Novartis Pharmaceuticals Corporation, East Hanover, NJ
Jeetvan Patel , Amrita Sawhney , Clare Byrne , Jackson Tang , Channing Yu
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Prostate Cancer
Track
Prostate Cancer - Advanced,Prostate Cancer - Localized
Sub Track
Quality of Care/Quality Improvement and Real-World Evidence
Citation
J Clin Oncol 41, 2023 (suppl 6; abstr 64)
DOI
10.1200/JCO.2023.41.6_suppl.64
Abstract #
64
Poster Bd #
B18
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Genitourinary Cancers Symposium
Real-world treatment (Tx) sequences and time to discontinuation (rwTTD) in the first-line (1L) metastatic castration-resistant prostate cancer (mCRPC) setting.
First Author: Emily Nash Smyth
Poster
2024 ASCO Genitourinary Cancers Symposium
Real-world treatment patterns in patients with BRCA 1/2-positive (BRCA+) metastatic castration-resistant prostate cancer (mCRPC) initiating first-line (1L) therapy.
First Author: Mehmet Asim Bilen
Poster
2023 ASCO Genitourinary Cancers Symposium
Characteristics of long-term responder (LTR) patients (pts) treated with androgen-receptor signaling inhibitors (ARSI) as a first-line treatment for metastatic castration-resistant prostate cancer (mCRPC): Real-world evidence from four high-volume institutions.
First Author: Orazio Caffo
Poster
2022 ASCO Quality Care Symposium
Real-world treatment patterns among men with metastatic castration-resistant prostate cancer (mCRPC) in the U.S. Medicare population.
First Author: Stephen J. Freedland